Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23826941 | 0.99 | NOTUM (0.76) | NOTUMCYP1A2 | |
| SCHEMBL23825726 | 0.88 | NOTUM (0.72) | NOTUMCYP1A2 | |
| Hydrochloric Acid SCHEMBL23826791 | 0.87 | NOTUM (0.70) | NOTUMCYP1A2 | |
| SCHEMBL23825539 | 0.85 | NOTUM (0.71) | NOTUMCYP1A2 | |
| SCHEMBL23825790 | 0.84 | NOTUM (0.67) | NOTUMCYP1A2 | |
| Hydrochloric Acid SCHEMBL23825983 | 0.84 | NOTUM (0.70) | NOTUMCYP1A2 | |
| Hydrochloric Acid SCHEMBL23827074 | 0.83 | NOTUM (0.66) | NOTUMCYP1A2 | |
| SCHEMBL23825714 | 0.83 | NOTUM (0.74) | NOTUMCYP1A2 | |
| Hydrochloric Acid SCHEMBL23826450 | 0.82 | NOTUM (0.73) | NOTUMCYP1A2 | |
| SCHEMBL23825849 | 0.80 | NOTUM (0.73) | NOTUMCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113302184-B | 1,3, 4-Oxadiazolinone compounds and medicaments | 日本新药株式会社 | 2024-11-22 | — | — | CN | claimed |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | claimed |
| EP-3882239-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2021-09-22 | — | — | EP | claimed |
| CN-113302184-B | 1,3, 4-Oxadiazolinone compounds and medicaments | 日本新药株式会社 | 2024-11-22 | — | — | CN | disclosed |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| EP-3882239-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2021-09-22 | — | — | EP | disclosed |
| CN-113302184-A | 1,3, 4-oxadiazolinone compounds and drugs | 日本新药株式会社 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | NOTUM 1103/4885CYP1A2 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.